ReviewFrontiers in chemistry2026
Advances in nanomaterial-enhanced immunosensors for ultra-sensitive tumor marker detection: Enabling early cancer diagnostics.
Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor markers are critical for early cancer diagnosis and directly influence treatment outcomes and patient survival. Although enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) show satisfactory selectivity in clinical applications, their limited sensitivity for low-abundance biomarkers, relatively long assay time, and reproducibility issues have promoted the development of advanced immunosensing platforms. Recent progress in nanomaterial synthesis has improved immunosensor performance by enhancing antibody immobilization, electron transfer, catalytic activity, signal amplification, photoelectric conversion, and luminescence efficiency. This review summarizes nanomaterial-enhanced immunosensors for clinically relevant tumor biomarkers, including carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), cancer antigen 153 (CA153), alpha-fetoprotein (AFP), cancer antigen 125 (CA125), cancer antigen 199 (CA199), and human epidermal growth factor receptor 2 (HER2). To reduce repetition and emphasize analytical performance rather than nominal material categories, this review adopts a platform-centered and mechanism-oriented framework. Electrochemical, photoelectrochemical, electrochemiluminescent, and chemiluminescent immunosensors are compared as major signal transduction platforms, with representative nanomaterials discussed according to their roles in antibody immobilization, electron-transfer acceleration, catalytic amplification, charge separation, luminescence regulation, magnetic enrichment, and interface stabilization. In addition, cross-platform comparisons of sensitivity, detection limit, specificity, recovery, assay time, storage stability, cost, scalability, and clinical applicability are provided to clarify the translational value of different sensing strategies. This comparative analysis highlights that clinical applicability is primarily determined by integrated platform performance, including sensitivity, stability, manufacturability, and compatibility with point-of-care testing, rather than by the use of a specific nanomaterial alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.